At a glance
ClinicalIndex Comparison RecordN/ACompleted· 708 enrolled
Drug / intervention
laparoscopic long limb roux-en-Y gastric bypassprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Homocysteine After Laparoscopic Roux-enY Gastric Bypass: a Comprehensive Evalutation in 708 Patients
In Brief
An observational study evaluating laparoscopic long limb roux-en-Y gastric bypass for Obesity, Morbid and 4 related conditions. Completed, enrolled 708 participants across 1 site.
Detailed Summary
Changes in homocysteine values after bariatric surgery remain controversially discussed. This is the first comprehensive summary to depict timeline changes in homocysteine levels following laparoscopic roux-en-Y gastric bypass.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Morbid, Homocystine; Metabolic Disorder, Bariatric Surgery Candidate, Folate Deficiency, Vitamin B 12 Deficiency
CountriesAustria
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2013
Primary CompletionSep 2017
First PostedApr 2018
TodayJul 2026
First PostedApr 5, 2018
Enrollment StartApr 9, 2013
Primary CompletionSep 11, 2017
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 8.2 years ago
Interventions
laparoscopic long limb roux-en-Y gastric bypassprocedure
standard laparoscopic roux-en-Y gastric bypass (biliopancreatic limb 40 to 60 cm, alimentary limb 150 cm)